Cue Biopharma, Inc. (LS:A426PN) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants Announced: about US$50M · US$33.21 a share Buyers: Cormorant Asset Management; Columbia Threadneedle Investments Use of proceeds: Further fund clinical development and general corporate purposes | Jul 10, 2026 |
| Private placement of pre-funded warrants and accompanying common stock warrants Announced: about US$30M · US$11 a share · Warrants at US$11 · Newbridge Securities Corporation Dealers: Newbridge Securities Corporation (lead) Use of proceeds: Advance the clinical pipeline, including acquiring and developing Ascendant-221, working capital and general corporate purposes | Apr 30, 2026 |
| Public offering of shares of common stock (or pre-funded warrants) and accompanying common stock warrants Announced: about US$10M · US$0.28 a share · Warrants at US$0.3 for 60 months · H.C. Wainwright & Co. +1 Dealers: H.C. Wainwright & Co. (lead), Newbridge Securities Corporation | Dec 19, 2025 |
| Public offering of common stock and accompanying common stock warrants, pre-funded warrants Closed: US$20M raised · US$0.79 a share · Warrants at US$0.79 for 60 months · Oppenheimer & Co. Inc. +1 Dealers: Oppenheimer & Co. Inc. (lead), Newbridge Securities Corporation | Aug 12, 2025 |